Table of Contents Author Guidelines Submit a Manuscript
Journal of Diabetes Research
Volume 2017, Article ID 7687098, 8 pages
https://doi.org/10.1155/2017/7687098
Review Article

Circulating Nesfatin-1 Levels and Type 2 Diabetes: A Systematic Review and Meta-Analysis

1Preventive Medicine Department, Grade 2014, School of Public Health, Qingdao University, Shandong, China
2Clinical Medicine Department, Grade 2014, Medical College, Qingdao University, Shandong, China
3School of Public Health, Qingdao University, Qingdao, China
4Physiology Department, Medical College, Qingdao University, Shandong, China
5Special Medicine Department, Medical College, Qingdao University, Shandong, China

Correspondence should be addressed to Jing Dong; moc.liamtoh@6gnijgnod

Received 17 May 2017; Revised 24 July 2017; Accepted 3 December 2017; Published 28 December 2017

Academic Editor: Daniela Foti

Copyright © 2017 Ting Zhai et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. S. Ohi, H. Shimizu, T. Satoh et al., “Identification of nesfatin-1 as a satiety molecule in the hypothalamus,” Nature, vol. 443, no. 7112, pp. 709–712, 2006. View at Publisher · View at Google Scholar · View at Scopus
  2. Y. Su, J. Zhang, Y. Tang, F. Bi, and J. N. Liu, “The novel function of nesfatin-1: anti-hyperglycemia,” Biochemical and Biophysical Research Communications, vol. 391, no. 1, pp. 1039–1042, 2009. View at Publisher · View at Google Scholar · View at Scopus
  3. M. Yang, Z. Zhang, C. Wang et al., “Nesfatin-1 action in the brain increases insulin sensitivity through Akt/AMPK/TORC2 pathway in diet-induced insulin resistance,” Diabetes, vol. 61, no. 8, pp. 1959–1968, 2012. View at Publisher · View at Google Scholar · View at Scopus
  4. M. Nakata, K. Manaka, S. Yamamoto, M. Mori, and T. Yada, “Nesfatin-1 enhances glucose-induced insulin secretion by promoting Ca2+ influx through L-type channels in mouse islet β-cells,” Endocrine Journal, vol. 58, no. 4, pp. 305–313, 2011. View at Publisher · View at Google Scholar · View at Scopus
  5. W. Pan, H. Hsuchou, and A. J. Kastin, “Nesfatin-1 crosses the blood-brain barrier without saturation,” Peptides, vol. 28, no. 11, pp. 2223–2228, 2007. View at Publisher · View at Google Scholar · View at Scopus
  6. R. A. DeFronzo, “The triumvirate: β-cell, muscle, liver: a collusion responsible for NIDDM,” Diabetes, vol. 37, no. 6, pp. 667–687, 1988. View at Publisher · View at Google Scholar
  7. C. Bogardus, “Metabolic abnormalities in the development of non-insulin dependent diabetes mellitus,” Diabetes Mellitus, pp. 459–467, 1996. View at Google Scholar
  8. Y. Guo, Y. Liao, G. Fang, J. Dong, and Z. Li, “Increased nucleobindin-2 (NUCB2) transcriptional activity links the regulation of insulin sensitivity in type 2 diabetes,” Journal of Endocrinological Investigation, vol. 36, no. 10, pp. 883–888, 2013. View at Google Scholar
  9. Z. Zhang, L. Li, M. Yang, H. Liu, G. Boden, and G. Yang, “Increased plasma levels of nesfatin-1 in patients with newly diagnosed type 2 diabetes mellitus,” Experimental and Clinical Endocrinology & Diabetes, vol. 120, no. 2, pp. 91–95, 2012. View at Publisher · View at Google Scholar · View at Scopus
  10. S. Algul, Y. Ozkan, and O. Ozcelik, “Serum nesfatin-1 levels in patients with different glucose tolerance levels,” Physiological Research, vol. 65, pp. 979–985, 2016. View at Google Scholar
  11. R. Dai, G. Deng, Z. Sun, Z. Liu, Y. Qian, and Y. Han, “Relation of serum and vitreous nesfatin-1 concentrations with diabetic retinopathy,” Journal of Clinical Laboratory Analysis, vol. 31, no. 5, article e22105, 2017. View at Publisher · View at Google Scholar
  12. Q. C. Li, H. Y. Wang, X. Chen, H. Z. Guan, and Z. Y. Jiang, “Fasting plasma levels of nesfatin-1 in patients with type 1 and type 2 diabetes and the nutrient-related fluctuation of nesfatin-1 level in normal humans,” Regulatory Peptides, vol. 159, no. 1-3, pp. 72–77, 2010. View at Publisher · View at Google Scholar · View at Scopus
  13. F. Liu, Q. Yang, N. Gao, F. Liu, and S. Chen, “Decreased plasma nesfatin-1 level is related to the thyroid dysfunction in patients with type 2 diabetes,” Journal of Diabetes Research, vol. 2014, Article ID 128014, 5 pages, 2014. View at Publisher · View at Google Scholar · View at Scopus
  14. J. Tang, Z. Yang, F. Liu, Y. Zhang, and J. Liu, “Changes in the serum levels of nesfatin-1 in type 2 diabetic patients with nephropathy,” Diabetes/Metabolism: Research & Reviews, vol. 31, p. 21, 2015. View at Google Scholar
  15. D. F. Stroup, J. A. Berlin, S. C. Morton et al., “Meta-analysis of observational studies in epidemiology: a proposal for reporting,” Journal of the American Medical Association, vol. 283, no. 15, pp. 2008–2012, 2008. View at Publisher · View at Google Scholar
  16. D. Moher, A. Liberati, J. Tetzlaff, D. G. Altman, and The PRISMA Group, “Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement,” PLoS Medicine, vol. 6, article e1000097, 2009. View at Publisher · View at Google Scholar · View at Scopus
  17. A. Stang, “Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses,” European Journal of Epidemiology, vol. 25, no. 9, pp. 603–605, 2010. View at Publisher · View at Google Scholar · View at Scopus
  18. H. Birnbaum and J. R. Slutsky, “Guiding comparative effectiveness research–a US perspective,” PharmacoEconomics, vol. 28, no. 10, pp. 839–842, 2010. View at Publisher · View at Google Scholar · View at Scopus
  19. D. Kuang, W. Chen, Y. Z. Song et al., “Association between the HSPA1B ± 1267A/G polymorphism and cancer risk: a meta-analysis of 14 case-control studies,” Asian Pacific Journal of Cancer Prevention, vol. 15, no. 16, pp. 6855–6861, 2014. View at Publisher · View at Google Scholar · View at Scopus
  20. R. DerSimonian and N. Laird, “Meta-analysis in clinical trials,” Controlled Clinical Trials, vol. 7, pp. 177–188, 1986. View at Publisher · View at Google Scholar · View at Scopus
  21. M. Egger, G. D. Smith, M. Schneider, and C. Minder, “Bias in meta-analysis detected by a simple, graphical test,” BMJ, vol. 315, no. 7109, pp. 629–634, 1997. View at Publisher · View at Google Scholar
  22. C. B. Begg and M. Mazumdar, “Operating characteristics of a rank correlation test for publication bias,” Biometrics, vol. 50, no. 4, pp. 1088–1101, 1994. View at Publisher · View at Google Scholar · View at Scopus
  23. A. AbuHanoud, V. Kasabri, and N. Bulayova, “Evaluation of oxytocin (OXT), endothelin-1 and nesfatin plasma concentrations in newly - diagnosed diabetic and non - diabetic patients with metabolic syndrome,” Jordan Journal of Pharmaceutical Sciences, vol. 9, no. 3, pp. 163–173, 2016. View at Publisher · View at Google Scholar
  24. A. Akour, V. Kasabri, N. Boulatova et al., “Levels of metabolic markers in drug-naive prediabetic and type 2 diabetic patients,” Acta Diabetologica, vol. 54, pp. 163–170, 2016. View at Publisher · View at Google Scholar · View at Scopus
  25. M. Nakata and T. Yada, “Role of NUCB2/nesfatin-1 in glucose control: diverse functions in islets, adipocytes and brain,” Current Pharmaceutical Design, vol. 19, no. 39, pp. 6960–6965, 2013. View at Publisher · View at Google Scholar · View at Scopus
  26. S. Khalili, M. S. Khaniani, F. Afkhami, and S. M. Derakhshan, “NUCB2/Nesfatin-1: a potent meal regulatory hormone and its role in diabetes,” Egyptian Journal of Medical Human Genetics, vol. 18, no. 2, pp. 105–109, 2017. View at Publisher · View at Google Scholar
  27. J. Dong, H. Xu, H. Xu et al., “Nesfatin-1 stimulates fatty-acid oxidation by activating AMP-activated protein kinase in STZ-induced type 2 diabetic mice,” PLoS One, vol. 8, no. 12, article e83397, 2013. View at Publisher · View at Google Scholar · View at Scopus
  28. S. Herpertz, R. Wagener, C. Albus et al., “Diabetes mellitus and eating disorders: a multicenter study on the comorbidity of the two diseases,” Journal of Psychosomatic Research, vol. 44, no. 3-4, pp. 503–515, 1998. View at Publisher · View at Google Scholar · View at Scopus
  29. G. H. Schernthaner and G. Schernthaner, “Insulin resistance and inflammation in the early phase of type 2 diabetes: potential for therapeutic intervention,” Scandinavian Journal of Clinical & Laboratory Investigation, vol. 65, Supplement 240, pp. 30–40, 2005. View at Publisher · View at Google Scholar
  30. C. C. Ozturk, S. Oktay, M. Yuksel, D. Akakin, A. Yarat, and O. Kasimay Cakir, “Anti-inflammatory effects of nesfatin-1 in rats with acetic acid - induced colitis and underlying mechanisms,” Journal of Physiology & Pharmacology, vol. 66, no. 5, pp. 741–750, 2015. View at Google Scholar
  31. D. Özsavcí, M. Erşahin, A. Şener et al., “The novel function of nesfatin-1 as an anti-inflammatory and antiapoptotic peptide in subarachnoid hemorrhage-induced oxidative brain damage in rats,” Neurosurgery, vol. 68, no. 6, pp. 1699–1708, 2011. View at Publisher · View at Google Scholar · View at Scopus